Nostrum Biodiscovery is a spin-off from the Barcelona Supercomputing Center (BSC-CNS) and the Institute for Research in Biomedicine (IRB), two of the most recognized Spanish international research centers.
Nostrum Biodiscovery provide advanced technologies in Molecular Modelling, with two areas of focus : therapeutics, e.g. small molecules design, targeted protein degradation, antibodies, immunologics and nucleic acids, and bio-based chemistry as in enzyme engineering.
Nostrum Biodiscovery’s customer-tailored solutions are based on state-of-the-art proprietary and 3rd-party software, combined with the latest development on AI. We use best in-class Molecular Modeling for data augmentation and fine-tuning of dedicated machine-learning algorithms.
With a focus on efficiency, innovation, and accessibility, Nostrum Biodiscovery is committed to providing cutting-edge solutions to the global scientific community. We have now clients in more than 12 countries and are currently expanding in Asia, Latin America while strengthening our presence in the US and Europe.
December 2015
Foundation
June 2016
NEOTEC - CDTi
July 2016
Seed capital from
Funcación Marcelino Botín
Jan 2018
1st-AI pharma project
Jan 2019
45% Revenue Generated from International Sales
December 2019
Senén Vilaró award to
the Best innovative startup
December 2020
Breakeven point
Jan 2023
72% CAGR (2years)
Jan 2024
95% of sales from international
September 2016
1st internal DD project
October 2016
First DD contract
December 2018
BioExcel project granted - H2020-EC
June 2019
First PCT granted for an NCE in cardiovascular therapeutic area
May 2019
Enzyme Engineering Division created
June 2019
EE first contract in Europe
August 2019
EE first contract in the USA
January 2020
First PluriZyme in the PDB
November 2020
Protein Engineering Congress EU Sponsor
May 2020
Nucleic Acids division created
June 2020
First client
May 2016
ED/MD is transferred
September 2016
PELE is transferred
February 2017
PELEplat 1.0 launch
August 2018
PELE++ success case
Paper with ESTEVE
October 2019
pyDock considered one of the best PPI software in CASP13-CAPRI experiment
November 2019
PELE++ success case
Paper with Almirall
December 2019
PELE++ success case
Paper with Janssen Pharmaceutica
July 2020
pyDock is transferred
September 2020
PELE++ success case
Paper with Emerald
PELEplat DD/EE/AI
Mark Mayhew
Director of Strategy
